Evaluation of Neuraminidase Enzyme Assays Using Different Substrates To Measure Susceptibility of Influenza Virus Clinical Isolates to Neuraminidase Inhibitors: Report of the Neuraminidase Inhibitor Susceptibility Network
Open Access
- 1 February 2003
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 41 (2), 742-750
- https://doi.org/10.1128/jcm.41.2.742-750.2003
Abstract
The increasing use of influenza virus neuraminidase (NA) inhibitors (NIs) necessitates the development of reliable methods for assessing the NI susceptibility of clinical isolates. We evaluated three NA inhibition assays against a panel of five clinical isolates each of influenza virus A/H1N1, A/H3N2, and B strains and four viruses with a defined resistance genotype (R292K, H274Y, R152K, and E119V). For fluorometric enzyme assay (FA) 1 (FA-1), 2′-(4-methylumbelliferyl)-α-d-N-acetylneuraminic acid (MUNANA) at 100 μM was used as the substrate, with pretitration of the virus input. For FA-2, MUNANA at 200 μM was used as the substrate, with a fixed 1:10 dilution of input virus. For the chemiluminescence (CL) assay, the 1,2-dioxetane derivative of sialic acid at 100 μM was used as the substrate, with pretitration of the virus. Four different operators repeated the assays several times in a blinded fashion with both zanamivir and oseltamivir carboxylate (GS4071) to determine intra- and interassay variations. Mean 50% inhibitory concentration (IC50) values were lower and generally less variable with the CL assay. FA-1 displayed greater variation than the CL assay or FA-2 and the highest IC50 values with zanamivir; FA-2 showed the highest values with oseltamivir, particularly for influenza virus B, and was more variable with zanamivir than was the CL assay. All three assays detected 40-fold or greater changes in IC50 values for the resistant viruses with at least one drug. Mixing experiments, whereby increasing fractions (0, 20, 40, 60, 80, and 100%) of NA from a known NI-resistant virus were mixed with the corresponding NI-sensitive parental NA, indicated that the resolution of IC50 values was clearer with the CL assay than with FA-2 for two of the resistant variants (R152K and E119V). The FA and CL methods were reliable for the detection of NI resistance, but all assays have certain limitations. Based on reproducibility, ease of automation, time required for the assay, and greater sensitivity, the CL assay was selected for future susceptibility testing of influenza virus isolates circulating globally.Keywords
This publication has 23 references indexed in Scilit:
- In Vitro Characterization of A-315675, a Highly Potent Inhibitor of A and B Strain Influenza Virus Neuraminidases and Influenza Virus ReplicationAntimicrobial Agents and Chemotherapy, 2002
- Treatment of influenza with neuraminidase inhibitors: virological implicationsPhilosophical Transactions Of The Royal Society B-Biological Sciences, 2001
- Selection of Influenza Virus Mutants in Experimentally Infected Volunteers Treated with OseltamivirThe Journal of Infectious Diseases, 2001
- Management of InfluenzaClinical Drug Investigation, 2000
- Resistance of influenza viruses to neuraminidase inhibitors — a reviewAntiviral Research, 2000
- Development of a Sensitive Chemiluminescent Neuraminidase Assay for the Determination of Influenza Virus Susceptibility to ZanamivirAnalytical Biochemistry, 2000
- Influenza virus neuraminidase inhibitorsThe Lancet, 2000
- A rational attack on influenzaNature, 1993
- Three-dimensional structure of the neuraminidase of influenza virus A/Tokyo/3/67 at 2·2 Å resolutionJournal of Molecular Biology, 1991
- Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-α-d-N-acetylneuraminate) substrateAnalytical Biochemistry, 1979